GlassScriptPhysician profile
Barry D Mangel
NPI 1801863931
$5,429.75
in general payments reported to CMS, 2019-2025
29 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $177 · 2021: $506 · 2022: $888 · 2023: $1,050 · 2024: $1,076 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.40 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $698.61 | 2019-2025 | |
| Teleflex LLC | $583.69 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $440.79 | 2019-2024 | Xarelto |
| Medtronic, INC. | $400.40 | 2022-2024 | Symplicity G3, Micra, Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $395.11 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $379.37 | 2019-2025 | |
| Corindus INC. | $300.15 | 2019 | |
| Amgen INC. | $280.25 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $239.56 | 2022-2025 | Xience Skypoint |
| Esperion Therapeutics, INC. | $219.28 | 2022-2024 | Nexletol |
| Siemens Medical Solutions USA, INC. | $194.70 | 2021-2024 | Naeotom Alpha, Magnetom Sola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.00 | 2019-2024 | Jardiance |
| Ge Healthcare | $142.80 | 2023 | |
| Merck Sharp & Dohme LLC | $127.64 | 2021-2025 | Verquvo |
| Cvrx, INC. | $124.97 | 2022-2023 | Barostim Neo System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $98.85 | 2022-2025 | |
| W. L. Gore & Associates, INC. | $95.99 | 2020-2021 | |
| Boston Scientific Corporation | $94.24 | 2019-2025 | Farapulse |
| Medtronic Vascular, INC. | $83.64 | 2019 | |
| Novo Nordisk INC | $77.69 | 2024-2025 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.89 | 2019-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $49.21 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $42.28 | 2024 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $39.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.56 | 2024 | |
| Edwards Lifesciences Corporation | $25.29 | 2019 | |
| Lundbeck LLC | $24.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.17 | 2021 | |
| Irhythm Technologies, INC. | $17.37 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Mangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.